| Project/Area Number |
24591880
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
General surgery
|
|---|
| Research Institution | Hiroshima University |
|---|
Principal Investigator |
TANAKA Yuka 広島大学, 医歯薬保健学研究院(医), 准教授 (90432666)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
OHDAN Hideki 広島大学, 医歯薬保健学研究院(医), 教授 (10363061)
ISHIYAMA Kohei 広島大学, 大学病院, 病院助教 (50437589)
|
|---|
| Project Period (FY) |
2012-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2013: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2012: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Keywords | NK細胞 / 肝臓癌 / 細胞免疫療法 |
|---|
| Outline of Final Research Achievements |
We have previously reported that IL-2-stimulated CD56+ cells derived from the liver exert vigorous cytotoxicity against HCC. To differentiate NK cells, we incubated bone marrow-derived CD34+ hematopoietic progenitor cells in 5% serum-supplemented X-VIVO-15 medium containing SCF, Flt-3, IL-7, and IL-15. These NK cells expressed NKp46, a specific receptor of NK cells, and were phenotypically similar to resident NK cells, i.e. they expressed TRAIL, NKG2D, and CD226. The propagated NK cells produced IFN-γ. The propagated NK cells exhibited vigorous cytotoxicity against HCC cell lines by using 51Cr release assay. We have also developed a method to differentiate CD34+ hematopoietic progenitor cells from fibroblast-derived iPS cells. The use of NK cells for immunotherapy relies on the availability of large numbers of purified NK cells with optimal anti-HCC activities. This adaptive immunotherapy with these cells may be a promising modality to prevent the recurrence of HCC after hepatectomy.
|
